Approach to Adjuvant Treatment of Endometrial Cancer

cindy0519 Member Posts: 173
edited March 2017 in Uterine Cancer #1

Approach to adjuvant treatment of endometrial cancer - UpToDate 3/17/17, 10:03 AM Page 1 of 11

Official reprint from UpToDate ©2017 UpToDate

The content on the UpToDate website is not intended nor recommended as a substitute for medical advice,

diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care

professional regarding any medical questions or conditions. The use of UpToDate content is governed by the

UpToDate Terms of Use. ©2017 UpToDate, Inc. All rights reserved.

Approach to adjuvant treatment of endometrial cancer

Authors: Steven C Plaxe, MD, Arno J Mundt, MD

Section Editors: Barbara Goff, MD, Don S Dizon, MD, FACP

Deputy Editor: Sadhna R Vora, MD

All topics are updated as new evidence becomes available and our peer review process is complete.

Literature review current through: Feb 2017. | This topic last updated: Jan 04, 2016.

INTRODUCTION — The treatment of endometrial cancer following surgical staging is based on the risk of

relapse and persistent disease, which is defined by the cancer stage at diagnosis and presence of prognostic

factors. This topic will cover the risk stratification criteria for newly diagnosed endometrial cancer. The treatment

by risk category is covered separately.

DEFINITION OF RISK BASED ON HISTOLOGY AND STAGE — For women with newly diagnosed endometrial

cancer, treatment is stratified based on the risk of disease recurrence, which is characterized using the stage of

disease (table 1), histology of the tumor, and other pathologic factors:



● (See "Treatment of low-risk endometrial cancer".)

● (See "Adjuvant treatment of intermediate-risk endometrial cancer".)

● (See "Adjuvant treatment of high-risk endometrial cancers".)

Low-risk endometrial cancer includes women with grade 1 endometrial cancer of endometrioid histology

that is confined to the endometrium (a subset of stage IA disease). The overall probability of recurrence in

these groups is very low following surgical treatment alone.

Intermediate-risk endometrial cancer includes women with uterine-limited cancer that invades the

myometrium (stage IA or IB) or demonstrates occult cervical stromal invasion (stage II). These groups have

a higher risk of recurrence than do patients whose tumors are confined to the endometrium (which defines

patients with low-risk endometrial cancer).

Among this subgroup, there are other adverse prognostic factors used to stratify women into high and lowintermediate-

risk. These include outer one-third myometrial invasion, grade 2 or 3 differentiation, or the

presence of lymphovascular invasion within the cancer. (See "Adjuvant treatment of intermediate-risk

Approach to adjuvant treatment of endometrial cancer - UpToDate 3/17/17, 10:03 AM Page 2 of 11

Staging evaluations and discussion of the role of the sentinel lymph node biopsy are discussed in detail

elsewhere. (See "Endometrial carcinoma: Pretreatment evaluation, staging, and surgical treatment", section on

'Pretreatment evaluation' and "Endometrial carcinoma: Pretreatment evaluation, staging, and surgical


OTHER PROGNOSTIC FACTORS — Beyond histology and stage, other factors may be used to inform the role

of adjuvant therapy beyond the risk-stratified approach described above. These include:

Lower uterine segment involvement — Women with otherwise low-risk disease who have involvement of the

lower uterine segment may be at a greater risk for nodal involvement. However, it is not clear if involvement of

the lower uterine segment represents an independent risk factor for survival. This topic is discussed in detail

separately. (See "Treatment of low-risk endometrial cancer".)

Positive peritoneal cytology — Approximately 11 percent of patients undergoing surgical staging have positive

peritoneal cytology, most commonly in the setting of advanced (extrauterine) disease [1]. However, positive

peritoneal cytology is no longer considered in the staging system for endometrial carcinoma to assign tumor (T)

stage (table 1) [2]. Despite this, the prognostic significance of isolated positive peritoneal washings in the

absence of extrauterine spread remains controversial, as illustrated in the following studies:

endometrial cancer", section on 'Definition of intermediate-risk'.)

High-risk endometrial cancer includes women with stage III or higher endometrial cancer, regardless of

histology or grade. However, women with a serous (USC) or clear cell (CC) carcinoma are deemed at high

risk, regardless of stage. These women are at a high risk of relapse and death.

A 2009 systematic review that included over 50 studies reported that the prognosis associated with a

positive peritoneal cytology varied according to the presence of other factors [3]. Women with positive

peritoneal cytology, but otherwise low-risk disease (grade 1 or 2, myometrial invasion <50 percent, no

cervical involvement, no lymphovascular space invasion) had a significantly lower rate of recurrence

compared with other women (4.1 versus 32 percent).

However, a 2012 analysis of 14,704 patients identified from the Surveillance, Epidemiology, and End

Results (SEER) registry reported that positive peritoneal cytology was an independent predictor of mortality,

regardless of histologic subtype, among women with early-stage (stage I to II) endometrial carcinoma [4].

The main results were:

Patients with high-risk factors (eg, grade 3 disease, clear cell or serous histology) were more likely to

have positive peritoneal cytology than those without high-risk factors (17.5 versus 7.5 percent,

respectively, p <0.0001).

The presence of positive peritoneal cytology predicted significantly poorer survival regardless of

histology and tumor grade compared with those with negative cytologic results.

The risk of death was significantly higher among women with positive peritoneal cytology compared

with those with negative peritoneal cytology and stage IA disease (hazard ratio [HR] 4.6, 95% CI 3.79-


Approach to adjuvant treatment of endometrial cancer - UpToDate 3/17/17, 10:03 AM Page 3 of 11

We do not routinely consider peritoneal cytology results by themselves in the formulation of a treatment plan for

patients with endometrial cancer and continue to make treatment decisions primarily based on extent of disease

(determined at staging) and final pathologic features. We agree with the 2009 International Federation of

Gynecology and Obstetrics (FIGO) staging guidelines for endometrial cancer and report cytology results

separately without adjustment to the T-stage [5]. (See "Endometrial carcinoma: Pretreatment evaluation, staging,

and surgical treatment", section on 'Staging and primary surgical treatment'.)

Older age — Older age has been associated with higher rates of clinical failure and survival in several [6-11] (but

not all [12]) studies. The association between age and prognosis can be illustrated by data from the Gynecologic

Oncology Group (GOG) protocol 33, in which five-year relative survival rates for women with clinical stage I and

II endometrial cancer stratified by age were as follows:

Whether age represents an independent prognostic factor is controversial. Women over the age of 65 have more

frequent deep myometrial invasion, high tumor grade, and advanced tumor stage [7,12-15]. Furthermore, less

aggressive therapy could also account for some of the poor outcomes seen in older patients [12,14,15]. As noted

above, age is used to categorize women with intermediate-risk disease into either a high or low-intermediate risk

group, which may influence treatment decisions. However, even when treated in uniform fashion, older women

seem to have higher recurrence rates and inferior survival compared with their younger counterparts. (See

'Definition of risk based on histology and stage' above.)

Black women — Race also factors into prognosis. Black women have a consistently poorer outcome than

Caucasians, an effect that is incompletely explained by imbalances in psychosocial, clinicopathologic, and

treatment factors [16-22]. Some of the racial disparity in survival has been attributed to a lower incidence of

good-prognosis (low-grade endometrioid) cancers in blacks and a higher incidence of high-risk (grade 3 and nonendometrioid)

tumors [23,24]. However, an alternative explanation for the worse survival is provided by emerging

data suggesting that at least in uterine serous cancers, blacks have a higher frequency of overexpressed or

amplified human epidermal growth factor receptor 2 (HER2) [25,26].

In contrast to Black women, Asian women appear to have a better survival relative to other populations, an effect

that is attributed at least in part to younger age at diagnosis. In data from the SEER of the National Cancer

Institute, 1 in 50 Asian women with uterine cancer was diagnosed before age 35 as compared with 1 in 150 white

women [27].

Molecular prognostic factors — A number of molecular factors hold promise for determining the prognostic

value of routine surgical and histologic characteristics. These include p53 and p16 overexpression, phosphatase

and tensin homolog (PTEN) mutations, markers of proliferation, microsatellite instability, tumor expression of

estrogen (ER) and/or progesterone (PR) receptors, or proteins involved in the phosphoinositide 3-kinase

● ≤40 years old – 96 percent

● 41 to 50 years old – 94 percent

● 51 to 60 years old – 87 percent

● 61 to 70 years old – 78 percent

● 71 to 80 years old – 71 percent

● ≥80 years old – 54 percent

Approach to adjuvant treatment of endometrial cancer - UpToDate 3/17/17, 10:03 AM Page 4 of 11

(PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway [28-41].

Until more data become available, however, they remain investigational and should not be incorporated into

clinical decision making. As examples:

OVERVIEW OF TREATMENT — All women with endometrial cancer should undergo surgical staging, especially

if the disease is not suspected to be metastatic. For these women, the treatment approach is based on final

pathology and the histologic type of cancer, which are used to define risk (see 'Definition of risk based on

histology and stage' above):

Low-risk endometrial cancer — For women with low-risk endometrial cancer, no adjuvant treatment is

indicated following surgery. However, some women may wish to preserve future fertility, despite a biopsy-proven

diagnosis of grade 1 endometrial cancer. These patients may be candidates for conservative treatment using

progestin therapy (eg, megestrol acetate), although careful selection of appropriate patients is necessary. (See

"Treatment of low-risk endometrial cancer".)

Intermediate-risk endometrial cancer — Women with intermediate-risk endometrial cancer benefit most from

postoperative radiation therapy (RT). However, some clinicians may offer adjuvant chemotherapy (with or without

In a report of 134 women who underwent complete surgical staging, p53 overexpression and high S phase

fraction (≥9 percent) in preoperative endometrial curettage specimens were independent, significant,

presurgical molecular determinants of outcome. The presence of both factors increased the risk of

recurrence sevenfold, and the risk of cancer-related death almost 10-fold when compared with women with

neither factor [29].

The absence of PR expression has been correlated with the presence of lymph node metastases and

inferior survival in some reports [31,32]. Absence of ER expression appears to have some prognostic value,